Study of BTK Inhibitor BGB-3111 in Chinese Participants With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
Status:
Completed
Trial end date:
2021-01-11
Target enrollment:
Participant gender:
Summary
Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity
or death, withdrawal of consent, lost to follow-up, or study termination from sponsor;
treatment (up to 3 years), safety follow up (28 days); survival follow-up until data cutoff
for final analysis.